Tags : Rinvoq

Pharma

AbbVie Reports Results of Rinvoq (upadacitinib) in P-III SELECT-PsA 2

Shots: The P-III SELECT-PsA 2 study involves assessing of Rinvoq (15/30mg) vs PBO in adult patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease-modifying anti-rheumatic drugs (bDMARDs) The P-III SELECT-PsA 2 study results: @12wks. patients achieved ACR20 (57%/64% vs 24%), ACR 50(32%/38% vs 5%), ACR 70 (9%/17% vs 0.5%); […]Read More

Regulatory

AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate

Shots: The CHMP positive opinion is based on P-III SELECT program including SELECT-NEXT, SELECT-BEYOND, SELECT-MONOTHERAPY, SELECT-COMPARE and SELECT-EARLY assessing Rinvoq in 4,400+ patients with mod. to sev. active RA In P-III studies, Rinvoq improved signs and symptoms of RA, inhibited radiographic progression and improved physical function, both as a monothx. and in combination with conventional […]Read More

Insights+

Insights+: The US FDA New Drug Approvals in August 2019

The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 31 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entity and 17 Biologics while breaking its past year’s records of approval. However, there is a significant […]Read More